Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically.

ABSTRACT: The management of multiple myeloma (MM) is challenging: An assortment of available drug combinations adds complexity to treatment selection, and treatment resistance frequently develops. Given the heterogeneous nature of MM, personalized testing tools are required to identify drug sensitivities. To identify drug sensitivities in MM cells, we established a drug testing pipeline to examine ex vivo drug responses. MM cells from 44 patients were screened against 30 clinically relevant single agents and 44 double- and triple-drug combinations. We observed variability in responses across samples. The presence of gain(1q21) was associated with low sensitivity to venetoclax, and decreased ex vivo responses to dexamethasone reflected the drug resistance observed in patients. Less heterogeneity and

SUBMITTER: Giliberto M 

PROVIDER: S-EPMC8936517 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature